{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"53","value":"39"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"34","value":"7"},{"groupId":"OG002","lowerLimit":"2","upperLimit":"31","value":"20"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"19","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"18"}],"units":"Participants"}],"description":"For myeloma, a complete response(CR, defined as Negative immunofixation(IFE) of the serum and urine, \\< 5% plasma cells in bone marrow(BM), Disappearance of plasmacytomas), stringent CR(sCR, defined as CR plus Normal serum FLC ratio, Absence of clonal cells in BM), very good partial response(VGPR, defined as PR plus Serum and urine M-component detectable by IFE but not on electrophoresis), partial response(PR, defined as a ≥ 50% reduction of serum M-protein and/or reduction in 24-h urinary M-protein by ≥ 90% or to \\<200 mg per 24 h), or minor response(MR, defined as ≥25% but \\< 49% reduction of serum M-protein and reduction in 24h urine M-protein by 50-89%) noted as the objective status. For lymphoma, a CR(defined as no evidence of measurable disease), or PR(defined as regression of measurable disease and no new sites of disease) noted as the objective status. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lymphoma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Phase II (Lymphoma Patients Receiving 20 mg LBL589)"},{"description":"Myeloma patients receive 20 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Phase II (Myeloma Patients Receiving 20 mg LBH589)"},{"description":"Lymphoma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Phase II (Lymphoma Patients Receiving 30/40 mg LBH589)"},{"description":"Myeloma patients receive 30 or 40 mg/day panobinostat (LBH589) PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Phase II (Myeloma Patients Receiving 30/40 mg LBH589)"}],"paramType":"NUMBER","populationDescription":"Patients who were enrolled in and completed Phase II and treated at a starting dose of 20 mg or 30/40 mg LBH589 were evaluated in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 12 courses","title":"Overall Response Rate (Phase II)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}